Targeted RNA-sequencing for the quantification of measurable residual disease in acute myeloid leukemia.

ABSTRACT: Great effort is spent on developing therapies to improve the dire outcomes of those diagnosed with acute myeloid leukemia. The methods for quantifying response to therapeutic intervention have however lacked sensitivity. Patients achieving a complete remission as defined by conventional cytomorphological methods therefore remain at risk of subsequent relapse due to disease persistence. Improved risk stratification is possible based on tests designed to detect this residual leukemic burden (measurable residual disease). However, acute myeloid leukemia is a genetically diverse set of diseases, which has made it difficult to develop a single, highly reproducible, and sensitive assay for measurable residual disease. Here we present the development of a digital targeted RNA-sequencing-based app

SUBMITTER: Dillon LW 

PROVIDER: S-EPMC6355494 | biostudies-literature | 2019 Feb

REPOSITORIES: biostudies-literature